Neil Schauer
Avaxia Biologics, USA
Title: AVX-470, an Orally-Delivered GI-Targeted anti-TNF Biobetter
Biography
Biography: Neil Schauer
Abstract
Avaxia Biologics is a clinical-stage biopharmaceutical company developing gut-targeted biobetter therapeutics. TNF is a clinically validated target in gut inflammation. Discussion will center on Avaxia’s orally-delivered, minimally absorbed anti-TNF biologic drug that acts locally in the GI tract. In contrast to first generation systemically delivered anti-TNFs, AVX-470 has low systemic exposure for greater safety, higher local concentration to drive efficacy, and the convenience of oral administration.
